CRISPR Therapeutics

Biotech & Life Sciences · Switzerland · Founded 2013 · IPO 2016

Gene-based medicines for patients with serious diseases

Valuation $3.07B

Revenue $40M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Featured in

Market map Computational Biology & Chemistry startups in Europe

Investors

15 investors on CRISPR Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Versant Ventures

Series B+ 14 investors entered at this stage

SR One

Clough Capital Partners

GSK

New Leaf Venture Partners

Vertex Holdings

NEA

Bristol-Myers Squibb

Celgene

Wellington Management

Bayer Global Investments

Abingworth

Franklin Templeton Investments

Vivo Capital

Vertex Pharmaceuticals

CRISPR Therapeutics mafia

Startups founded by CRISPR Therapeutics alumni

Former CRISPR Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Zag BioEst. 2022

JKJohn KulmanUnited States

Signal score92

Clade TherapeuticsEst. 2020

Chad CowanUnited States

Signal score62

Vernal BiosciencesEst. 2021

Christian CobaughUnited States

Signal score60

AirNexis TherapeuticsEst. 2025

Maria FardisUnited States

Signal score56

Book a demo to explore the full alumni network →

Global footprint

Where CRISPR Therapeutics has talent and traffic

Workforce by country

6 countries with
team presence

🇺🇸 United States97.6%

🇨🇦 Canada1.1%

🇬🇧 United Kingdom0.3%

🇮🇳 India0.3%

🇧🇪 Belgium0.3%

Top 5 of 6 shown

Web traffic by country

120K monthly visits
across markets

🇺🇸 United States40.3%

🇮🇩 Indonesia5.1%

🇨🇦 Canada4.7%

🇦🇺 Australia4.3%

🇮🇳 India3.8%

Top 5 markets shown

Talent graph

The shape of CRISPR Therapeutics's talent

Dealroom maps CRISPR Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

21 standout operatorsDealroom-flagged across the org

2 AI specialistspinpointed by name

344 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock CRISPR Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$112M patent portfolio · 109 active families

Estimated portfolio value

$112M

3.6% of market cap · 7.1× smaller than top peer BioNTech ($788M)

109 active patent families

Where CRISPR Therapeutics innovates BioinformaticsCellCell biologyEx vivoGenome editing

Where CRISPR Therapeutics concentrates vs peers

Each axis is a top-10 topic across CRISPR Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about CRISPR Therapeutics

An AI-synthesized read of the highest-engagement posts about CRISPR Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CRISPR Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles